Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) is now available.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced changes to its Nomination Committee, appointing Ms. Fu Dawei and Dr. Kendall Arthur Smith as new members. These changes align with upcoming amendments to the Hong Kong Stock Exchange’s Listing Rules and Corporate Governance Code, aiming to enhance the company’s governance practices and board diversity.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in Shanghai, China. It operates in the healthcare industry, focusing on the development of innovative cancer immunotherapy treatments.
Average Trading Volume: 5,194,140
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.61B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.